Inhibition of RIP1 using antisense oligonucleotides (ASOs) has been shown to reduce diet-induced obesity, improve glucose homeostasis, and decrease insulin resistance in mice (Karunakaran et al, 2020), corroborating the beneficial effects observed in mice treated prophylactically with RIPA-56 (Majdi et al, 2020). Here, RIPK1 is linked to obesity due to melanocortin 4 receptor deficiency.